Current therapeutic drugs for type 2 diabetes, still useful after 50 years?

Anesthesia and Analgesia

Volumn 108, Issue 6, 2009, Pages 1727-1730

  Hall, George M ^a   Nicholson, Grainne ^a  

^a ST GEORGE S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA GLUCOSIDASE INHIBITOR; ANTIDIABETIC AGENT; BIGUANIDE; BIGUANIDE DERIVATIVE; EXENDIN 4; GLITAZONE DERIVATIVE; INSULIN; MEGLITINIDE; METFORMIN; PRAMLINTIDE; SITAGLIPTIN; SULFONYLUREA DERIVATIVE;

ABDOMINAL PAIN; DIARRHEA; DRUG EFFICACY; DRUG INFORMATION; DRUG RESEARCH; EDITORIAL; GASTROINTESTINAL SYMPTOM; HUMAN; HYPOGLYCEMIA; INCREASED APPETITE; LACTIC ACIDOSIS; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; SIDE EFFECT; TASTE DISORDER; TREATMENT FAILURE; WEIGHT GAIN; DIABETES MELLITUS; HISTORY; NOTE; TREATMENT OUTCOME;

DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 2; HISTORY, 20TH CENTURY; HUMANS; HYPOGLYCEMIC AGENTS; METFORMIN; TREATMENT OUTCOME;

EID: 66349083220     PISSN: 00032999     EISSN: None     Source Type: Journal    
DOI: 10.1213/ane.0b013e3181a6ad5c     Document Type: Editorial

References (41)

1. The global challenge of diabetes. Lancet 2008;371:1723
2. Lipscombe LL, Hux JE. Trends in diabetic prevalence, incidence and mortality in Ontario, Canada 1995-2005: a population-based study. Lancet 2007;369:750-56
3. Chen D, Lee SL, Peterfreund RA. New therapeutic agents for diabetes mellitus: implications for anesthetic management. Anesth Analg 2009;108:1803-10
4. Luna B, Feinglos MN. Oral agents in the management of type 2 diabetes mellitus. Am Fam Physician 2001;63:1747-56
5. Feinglos MN, Bethel MA. Treatment of type 2 diabetes mellitus. Med Clin North Am 1998;82:757-90
6. Luna B, Hughes AT, Feinglos MN. The use of insulin secretagogues in the treatment of type 2 diabetes. Prim Care 1999;26: 895-915
7. Kelley DE. Effects of weight loss on glucose homeostasis in NIDDM. Diabetes Rev 1995;3:366-77
8. Feinglos MN, Bethel MA. Therapy of type 2 diabetes, cardiovascular death, and the UGDP. Am Heart J 1999;138:346-52
9. Sheehan MT. Current therapeutic opinion in type 2 diabetes mellitus: a practical approach. Clin Med Res 2003;1:189-200
10. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-53
11. Kahn SE, Haffner SM, Heise MA, Herman WH, Holman RR, Jones NP, Kravitz BG, Lachin JM, O'Neill MC, Zinman B, Viberti G; ADOPT Study Group. Glycaemic durability of rosiglitazone, metformin or glyburide monotherapy. N Engl J Med 2006;355:2427-43
12. Stumvoll M, Häring HU, Matthaei S. Metformin. Endocr Res 2007;32:39-57
13. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998;352:854-65
14. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008;359:1577-89
15. Stumvoll M, Nurjhan N, Perriello G, Dailey G, Gerich JE. The metabolic effects of metformin in non-insulin-dependent diabetes mellitus. N Engl J Med 1995;333:550-4
16. Bolen S, Feldman L, Vassy J, Wilson L, Yeh HC, Marinopoulis S, Wiley C, Selvin E, Wilson R, Bass EB, Brancati FL. Systematic review: comparative effectiveness and safety of oral medications for type 2 diabetes mellitus. Ann Intern Med 2007;147: 386-99
17. Holstein A, Stumvoll M. Contraindications can damage your health-is metformin a case in point? Diabetologia 2005;48: 2454-9
18. Fonseca VA, Kulkarni KD. Management of type 2 diabetes: oral agents, insulin and injectables. J Am Diet Assoc 2008;108: S29-S33
19. Fonseca V, Rosenstock J, Patwardhan R, Salzman A. Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized controlled trial. JAMA 2000;283:1695-702
20. Phillips LS, Grunberger G, Miller E, Patwardhan R, Rappaport EB, Salzman A; Rosiglitazone Clinical Trials Sudy Group. Once-and twice-daily dosing with rosiglitazone improves glycemic control in patients with type 2 diabetes. Diabetes Care 2001;24:308-15
21. Bell DS, Ovalle F. Tissue triglyceride levels in type 2 diabetes and the role of thiazolidinediones in reversing the effects of tissue hypertriglyceridemia: review of the evidence in animals and humans. Endocr Pract 2001;7:135-8
22. Okuno A, Tamemoto H, Tobe K, Ueki K, Mori Y, Iwamoto K, Umesono K, Akanuma Y, Fujiwara T, Horikoshi H, Yazaki Y, Kadowaki T. Troglitazone increases the number of small adipocytes without the change of white adipose tissue mass in obese Zucker rats. J Clin Invest 1998;101:1354-61
23. Adams M, Montague CT, Prins JB, Holder JC, Smith SA, Sanders L, Digby JE, Sewter CP, Lazar MA, Chatterjee VK, O'Rahilly S. Activators of peroxisome proliferator-activated receptor gamma have depot-specific effects on human preadipocyte differentiation. J Clin Invest 1997;100:3149-53
24. McGuire DK, Inzucchi SE. New drugs for the treatment of diabetes mellitus: part i: thiazolidinediones and their evolving cardiovascular implications. Circulation 2008;117:440-9
25. Haffner SM, Greenberg AS, Weston WM, Chen H, Williams K, Freed MI. Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Circulation 2002;106:679-84
26. Marx N, Imhof A, Froehlich J, Siam L, Ittner J, Wierse G, Schmidt A, Maerz W, Hombach V, Koenig W. Effect of rosiglitazone treatment on soluble CD40L in patients with type 2 diabetes and coronary artery disease. Circulation 2003;107: 1954-7
27. Caballero AE, Saouaf R, Lim SC, Hamdy O, Abou-Elenin K, O'Connor C, Logerfo FW, Horton ES, Veves A. The effects of troglitazone, an insulin-sensitizing agent, on the endothelial function in early and late type 2 diabetes: a placebo-controlled randomized clinical trial. Metabolism 2003;52:173-80
28. Forst T, Lubben G, Hohberg C, Kann P, Sachara C, Gottschall V, Friedrich C, Rosskopf R, Pfutzner A. Influence of glucose control and improvement of insulin resistance on microvascular blood flow and endothelial function in patients with diabetes mellitus type 2. Microcirculation 2005;12:543-50
29. Chiquette E, Ramirez G, Defronzo R. A meta-analysis comparing the effect of thiazolidinediones on cardiovascular risk factors. Arch Intern Med 2004;164:2097-104
30. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007;356:2457-71
31. Dormandy JA, Charbonnel B, Eckland DJ, Erdmann E, Massi-Benedetti M, Moules IK, Skene AM, Tan MH, Lefèbvre PJ, Murray GD, Standl E, Wilcox RG, Wilhelmsen L, Betteridge J, Birkeland K, Golay A, Heine RJ, Korányi L, Laakso M, Mokán M, Norkus A, Pirags V, Podar T, Scheen A, Scherbaum W, Schernthaner G, Schmitz O, Skrha J, Smith U, Taton J; PROactive investigators. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive study (prospective pioglitazone clinical trial in macrovascular events): a randomised controlled trial. Lancet 2005;366:1279-89
32. McAfee AT, Koro C, Landon J, Ziyadeh N, Walker AM. Coronary heart disease outcomes in patients receiving antidiabetic agents. Pharmacoepidemiol Drug Saf 2007;16:711-25
33. ACCORD Study Group, Buse JB, Bigger JT, Byington RP, Cooper LS, Cushman WC, Friedewald WT, Genuth S, Gerstein HC, Ginsberg HN, Goff DC Jr, Grimm RH Jr, Margolis KL, Probstfield JL, Simons-Morton DG, Sullivan MD. Action to control cardiovascular risk in diabetes (ACCORD) trial. Design and methods. Am J Cardiol 2007;99:S21-S33
34. Gerstein HC, Miller ME, Byington RP, Goff DC Jr, Bigger JT, Buse JB, Cushman WC, Genuth S, Ismail-Beigi F, Grimm RH Jr, Probstfield JL, Simons-Morton DG, Friedewald WT. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008;358:2545-59
35. Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R, Zinman B; American Diabetes Association; European Association for Study of Diabetes. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. Diabetes Care 2009;32: 193-203
36. Woo V. Important differences; Canadian Diabetes Association 2008 clinical practice guidelines and the consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 2009;52:S52-S53
37. Home PD, Jones NP, Pocock SJ, Beck-Nielsen H, Gomis R, Hanefeld M, Komajda R, Curtis P; RECORD Study Group. Rosiglitazone RECORD study: glucose control outcomes at 18 months. Diabet Med 2007;24:626-34
38. Wyne KL, Mora PF. Insulin therapy in type 2 diabetes. Endocr Res 2007;32:71-107
39. Scheen AJ. Exenatide once weekly in type 2 diabetes. Lancet 2008;372:1197-8
40. Amori RE, Lau J, Pittas AG. Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. JAMA 2007;298:194-206
41. Liu G. Technology evaluation: ISIS-113715. Curr Opin Mol Ther 2004;6:331-6